Eli Lilly (NYSE: LLY) has reported strong revenues for the third quarter, with blockbuster diabetes med Mounjaro (tirzepatide) doing much of the heavy lifting.
A stellar $1.4 billion in sales makes clear the trajectory of growth for the innovative product, which has only been available for a little over a year. Analysts had forecast sales of around $1.3 billion.
Other standout products include Verzenio (abemaciclib) and Jardiance (empagliflozin), with the $1.4 billion sale of rights for Zyprexa (olanzapine) also making a significant contribution to the balance sheet.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze